Factors That May Affect Appropriateness According to general clinical guidance referenced in published sources, growth hormone secretagogues may not be appropriate for individuals with certain contraindications including active malignancies, uncontrolled diabetes, or other conditions that a clinician would evaluate during the prescribing process
BPC-157 has a half-life of less than 30 minutes, yet its effects persist for weeks after a treatment cycle
2017;12:e0189310
In briefing documents for the meeting, the FDAs experts said there is a lack of evidence on effectiveness and safety to justify letting pharmacies make the peptides that the panel will review
[DOI] [PubMed] [Google Scholar] 17.Gwyer D., Wragg N.M., Wilson S.L
These could include local irritation, tissue damage, and in rare cases, systemic allergic reactions